These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 23972060)

  • 1. Primary objective of study of sitagliptin in patients with ESRD on dialysis.
    Arjona Ferreira JC; Golm GT; Goldstein BJ
    Am J Kidney Dis; 2013 Sep; 62(3):642. PubMed ID: 23972060
    [No Abstract]   [Full Text] [Related]  

  • 2. In reply to 'Primary objective of study of sitagliptin in patients with ESRD on dialysis'.
    St Peter WL; Weinhandl ED; Flessner MF
    Am J Kidney Dis; 2013 Sep; 62(3):642-3. PubMed ID: 23972059
    [No Abstract]   [Full Text] [Related]  

  • 3. Sitagliptin--another option for managing type 2 diabetes in dialysis patients?
    St Peter WL; Weinhandl ED; Flessner MF
    Am J Kidney Dis; 2013 Apr; 61(4):532-5. PubMed ID: 23497767
    [No Abstract]   [Full Text] [Related]  

  • 4. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes.
    Nomiyama T; Akehi Y; Takenoshita H; Nagaishi R; Terawaki Y; Nagasako H; Kudo T; Kodera T; Kobayashi K; Urata H; Yanase T;
    Diabetes Res Clin Pract; 2012 Feb; 95(2):e27-8. PubMed ID: 21899912
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial.
    Arjona Ferreira JC; Corry D; Mogensen CE; Sloan L; Xu L; Golm GT; Gonzalez EJ; Davies MJ; Kaufman KD; Goldstein BJ
    Am J Kidney Dis; 2013 Apr; 61(4):579-87. PubMed ID: 23352379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure?
    Bhatt DL; Cavender MA
    JACC Heart Fail; 2014 Dec; 2(6):583-5. PubMed ID: 24998081
    [No Abstract]   [Full Text] [Related]  

  • 7. Should we be reassured about sitagliptin?
    Segal J
    BMJ; 2013 May; 346():f3051. PubMed ID: 23674336
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents.
    Fang V; Wazny LD; Raymond CB
    CANNT J; 2012; 22(1):30-6; quiz 37-8. PubMed ID: 22558681
    [No Abstract]   [Full Text] [Related]  

  • 9. Dipeptidyl peptidase-4 inhibitors--emerging player for vascular protection.
    Satoh K
    Circ J; 2013; 77(5):1156-7. PubMed ID: 23386273
    [No Abstract]   [Full Text] [Related]  

  • 10. [Sitagliptin].
    Taéron C
    Rev Infirm; 2008 Oct; (144):46-8. PubMed ID: 19009789
    [No Abstract]   [Full Text] [Related]  

  • 11. Where is the evidence based on hard endpoints for the safety and effectiveness of sitagliptin in type 2 diabetes?
    de Oliveira JM
    BMJ; 2013 Jun; 346():f3568. PubMed ID: 23737277
    [No Abstract]   [Full Text] [Related]  

  • 12. Dipeptidyl-peptidase-4 inhibitors for treatment of type 2 diabetes.
    Kripke C
    Am Fam Physician; 2009 Mar; 79(5):372. PubMed ID: 19275065
    [No Abstract]   [Full Text] [Related]  

  • 13. [Incretin enhancer: sitagliptin].
    Kondo M; Tanizawa Y
    Nihon Rinsho; 2011 May; 69(5):859-63. PubMed ID: 21595272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus.
    Stafford S; Elahi D; Meneilly GS
    J Am Geriatr Soc; 2011 Jun; 59(6):1148-9. PubMed ID: 21668924
    [No Abstract]   [Full Text] [Related]  

  • 15. [Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin].
    Perusicová J
    Vnitr Lek; 2007 Oct; 53(10):1109-13. PubMed ID: 18072437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of a study to evaluate the effects of sitagliptin on atherosclerosis in patients with diabetes mellitus: PROLOGUE study.
    Oyama J; Ishizu T; Sato Y; Kodama K; Bando YK; Murohara T; Node K
    Int J Cardiol; 2014 Jun; 174(2):383-4. PubMed ID: 24768387
    [No Abstract]   [Full Text] [Related]  

  • 17. Sitagliptin combined with sulphonylureas: new indication. Other treatments are preferable.
    Prescrire Int; 2009 Feb; 18(99):14-5. PubMed ID: 19391232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics].
    MMW Fortschr Med; 2014 Jul; 156(13):74-5. PubMed ID: 25318234
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.
    Tremblay AJ; Lamarche B; Deacon CF; Weisnagel SJ; Couture P
    Diabetes Obes Metab; 2011 Apr; 13(4):366-73. PubMed ID: 21226820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
    Abel T; Fehér J
    Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.